New hope for tough cancers: testing a Two-Pronged attack on recurrent sarcomas
NCT ID NCT01858168
Summary
This early-stage study tested the safety of a new combination of drugs for adults whose Ewing's sarcoma or rhabdomyosarcoma had returned or spread after standard chemotherapy. The main goal was to find the highest dose of the drugs olaparib and temozolomide (and sometimes a third drug, irinotecan) that patients could tolerate. Researchers also began gathering initial information on whether this combination could help shrink these difficult-to-treat cancers.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RHABDOMYOSARCOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Boston Children's Hospital
Boston, Massachusetts, 02115, United States
-
Brigham and Women's Hospital
Boston, Massachusetts, 02215, United States
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
-
St. Jude's Children's Research Hospital
Memphis, Tennessee, 38105, United States
Conditions
Explore the condition pages connected to this study.